Ma Yuexing, Zheng Haoyi, Liu Simin, Yuan En, Qiao Xin, Dai Zhang, Wu Wenli, Pan Rongbin
College of Chinese Medicine, China Pharmaceutical University, Nanjing, Jiangsu, China.
Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Front Pharmacol. 2025 Mar 28;16:1469949. doi: 10.3389/fphar.2025.1469949. eCollection 2025.
The Tibetan medicinal botanical drug Taoerqi has long been recognized for its anti-inflammatory, antibacterial, and tumor-inhibitory properties.
Botanical drug focuses on the isolation and characterization of secondary metabolites from , an endophytic bacterium isolated from Taoerqi roots. The metabolites were obtained through fermentation and purification processes and were evaluated for their anti-breast cancer activities using cellular assays and transcriptomic analysis. Key regulatory targets, including SARM1, RGS5, PROM2, and BAG1, were identified through bioinformatics analysis and validated using qPCR and Western blotting. Furthermore, a clinical risk assessment model was constructed using breast cancer transcriptome databases to explore the potential prognostic value of these targets.
The secondary metabolites from exhibit significant anti-tumor effects and highlight their potential molecular mechanisms in breast cancer regulation.
This study provides insights into the therapeutic potential of these metabolites and lays the groundwork for future preclinical and investigations.
藏药植物塔尔七长期以来因其抗炎、抗菌和抑瘤特性而受到认可。
植物药专注于从塔尔七根部分离出的内生细菌中分离和鉴定次生代谢产物。这些代谢产物通过发酵和纯化过程获得，并使用细胞试验和转录组分析评估其抗乳腺癌活性。通过生物信息学分析鉴定了包括SARM1、RGS5、PROM2和BAG1在内的关键调控靶点，并使用qPCR和蛋白质印迹法进行验证。此外，利用乳腺癌转录组数据库构建了临床风险评估模型，以探索这些靶点的潜在预后价值。
内生细菌的次生代谢产物具有显著的抗肿瘤作用，并突出了它们在乳腺癌调控中的潜在分子机制。
本研究深入了解了这些代谢产物的治疗潜力，为未来的临床前和临床研究奠定了基础。
